Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127116551 | 12711655 | 1 | I | 20160824 | 20160902 | 20160902 | EXP | JP-BAYER-2016-167405 | BAYER | ARIYAMA Y, SAITO M, HIDAKA S, KANAZAWA S, NAGAOKA S, BABA S, ET. AL. A CASE OF ALVEOLAR HEMORRHAGE DURING ANTICOAGULANT/ANTIPLATELET THERAPY FOR STROKE IN PREGNANCY. TOKYO JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2016;65(3):473-477 | 34.00 | YR | A | F | Y | 44.40000 | KG | 20160902 | MD | JP | JP |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127116551 | 12711655 | 1 | PS | ACETYLSALICYLIC ACID({=100 mg) | ASPIRIN | 1 | Oral | 100 MG, QD | Y | 21317 | 100 | MG | TABLET | QD | |||||
127116551 | 12711655 | 2 | SS | ACETYLSALICYLIC ACID({=100 mg) | ASPIRIN | 1 | Y | 21317 | TABLET | ||||||||||
127116551 | 12711655 | 3 | SS | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | Oral | 75 MG, QD | 0 | 75 | MG | QD | |||||||
127116551 | 12711655 | 4 | SS | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | 0 | ||||||||||||
127116551 | 12711655 | 5 | SS | HEPARIN | HEPARIN SODIUM | 1 | 10000 U, QD | 0 | 10000 | IU | QD | ||||||||
127116551 | 12711655 | 6 | SS | HEPARIN | HEPARIN SODIUM | 1 | 0 | ||||||||||||
127116551 | 12711655 | 7 | SS | MAGNESIUM SULFATE. | MAGNESIUM SULFATE | 1 | 0 | ||||||||||||
127116551 | 12711655 | 8 | SS | RITODRINE | RITODRINE | 1 | 0 | ||||||||||||
127116551 | 12711655 | 9 | SS | RITODRINE | RITODRINE | 1 | INCREASED DOSE | 0 | |||||||||||
127116551 | 12711655 | 10 | SS | RITODRINE | RITODRINE | 1 | 133 ?G/MIN | 0 | |||||||||||
127116551 | 12711655 | 11 | SS | RITODRINE | RITODRINE | 1 | 83 ?G/MIN AND MG 1.6 G/H. | 0 | |||||||||||
127116551 | 12711655 | 12 | C | PLATELETS | HUMAN PLATELET, ALLOGENIC | 1 | DAILY DOSE 10 DF | 0 | 10 | DF | |||||||||
127116551 | 12711655 | 13 | C | RED CELLS MAP | HUMAN RED BLOOD CELL | 1 | DAILY DOSE 4 DF | 0 | 4 | DF | |||||||||
127116551 | 12711655 | 14 | C | CILOSTAZOL. | CILOSTAZOL | 1 | 200 MG, QD | 0 | 200 | MG | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127116551 | 12711655 | 1 | Cerebellar infarction |
127116551 | 12711655 | 2 | Cerebellar infarction |
127116551 | 12711655 | 3 | Basilar artery stenosis |
127116551 | 12711655 | 4 | Brain stem infarction |
127116551 | 12711655 | 5 | Basilar artery stenosis |
127116551 | 12711655 | 6 | Brain stem infarction |
127116551 | 12711655 | 7 | Threatened labour |
127116551 | 12711655 | 8 | Threatened labour |
127116551 | 12711655 | 9 | Threatened labour |
127116551 | 12711655 | 10 | Threatened labour |
127116551 | 12711655 | 11 | Threatened labour |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127116551 | 12711655 | OT |
127116551 | 12711655 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127116551 | 12711655 | Basilar artery stenosis | |
127116551 | 12711655 | Brain stem infarction | |
127116551 | 12711655 | Contraindicated product administered | |
127116551 | 12711655 | Drug administration error | |
127116551 | 12711655 | Labelled drug-drug interaction medication error | |
127116551 | 12711655 | Maternal exposure during pregnancy | |
127116551 | 12711655 | Premature delivery | |
127116551 | 12711655 | Pulmonary alveolar haemorrhage | |
127116551 | 12711655 | Stevens-Johnson syndrome | |
127116551 | 12711655 | Threatened labour |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |